Abdulaziz Almalik

Dr. Abdulaziz Almalik


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
SAShahad K. Alsaiari
Shahad K. Alsaiari
SQSomayah S. Qutub
Somayah S. Qutub
SSShichao Sun
Shichao Sun
WBWalaa Baslyman
Walaa Baslyman
MAMansour Aldehaiman
Mansour Aldehaiman
NKNiveen Khashab
Niveen Khashab
Delivery of antibodies using smart frameworks affords sustained and targeted activation of T cells for improved immunotherapy.

1 August 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
HOHaneen Waleed Omar
Haneen Waleed Omar
JCJonas Croissant
Jonas Croissant
KAKholod Alamoudi
Kholod Alamoudi
SAShahad Alsaiari
Shahad Alsaiari
IAIbrahim Alradwan
Ibrahim Alradwan
NKNiveen Khashab
Niveen Khashab

15 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
GPGundula Povysil
Gundula Povysil
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
NSNing Shang
Ning Shang
CWChen Wang
Chen Wang
AKAtlas Khan
Atlas Khan
KKKrzysztof Kiryluk
Krzysztof Kiryluk
A recent report found that rare predicted loss-of-function (pLOF) variants across 13 candidate genes in TLR3- and IRF7-dependent type I IFN pathways explain up to 3.5% of severe COVID-19 cases. We performed whole-exome or whole-genome sequencing of 1,864 COVID-19 cases (713 with severe and 1,151 with mild disease) and 15,033 ancestry-matched population controls across 4 independent COVID-19 biobanks. We tested whether rare pLOF variants in these 13 genes were associated with severe COVID-19. We identified only 1 rare pLOF mutation across these genes among 713 cases with severe COVID-19 and observed no enrichment of pLOFs in severe cases compared to population controls or mild COVID-19 cases. We found no evidence of association of rare LOF variants in the 13 candidate genes with severe COVID-19 outcomes.

20 December 2021 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
ETEssam Tawfik
Essam Tawfik
ATAbdulkader F. Tawfik
Abdulkader F. Tawfik
AAAreej M. Alajmi
Areej M. Alajmi
MBMoutaz Y. Badr
Moutaz Y. Badr
AAAhmed Al-Jedai
Ahmed Al-Jedai
AAAbdulaziz Almalik
Abdulaziz Almalik
Local production of pharmaceuticals plays a vital role in maintaining resilience of national healthcare systems, especially when it comes to facilitating access to needed medicines and decreasing exposure to imports and international supply chains. Pharma is a research-intensive industry and the systemic lack of governance and support to R&D activities in this sector, among other host of related issues such as unsupportive regulatory regimes and human resources capacity limitations, is one of the major impediments to the diversifying of locally produced pharmaceuticals portfolio. In this review, an overview of the current pharmaceutical production system in Saudi Arabia, its major challenges, and proposed remedies to address them will be highlighted.

15 July 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SMSalam Massadeh
Salam Massadeh
Mustafa E. OmerMustafa E. Omer
Mustafa E. Omer
AAAsmaa Alterawi
Asmaa Alterawi
Rizwan AliRizwan Ali
Rizwan Ali
FAFayez H Alanazi
Fayez H Alanazi
Alaa Eldeen Bakry YassinAlaa Eldeen Bakry Yassin
Alaa Eldeen Bakry Yassin
Purpose: The aim of this work is to optimize a polyethylene glycolated (PEGylated) polymer–lipid hybrid nanoparticulate system for the delivery of anastrozole (ANS) to enhance its biopharmaceutical attributes and overall efficacy. Methods: ANS loaded PEGylated polymer–lipid hybrid nanoparticles (PLNPs) were prepared by a direct emulsification solvent evaporation method. The physical incorporation of PEG was optimized using variable ratios. The produced particles were evaluated to discern their particle size and shape, zeta-potential, entrapment efficiency, and physical stability. The drug-release profiles were studied, and the kinetic model was analyzed. The anticancer activity of the ANS PLNPs on estrogen-positive breast cancer cell lines was determined using flow cytometry. Results: The prepared ANS-PLNPs showed particle sizes in the range of 193.6 ± 2.9 to 218.2 ± 1.9 nm, with good particle size uniformity (i.e., poly-dispersity index of around 0.1). Furthermore, they exhibited relatively low zeta-potential values ranging from −0.50 ± 0.52 to 6.01 ± 4.74. The transmission electron microscopy images showed spherical shape of ANS-PLNPs and the compliance with the sizes were revealed by light scattering. The differential scanning calorimetry DSC patterns of the ANS PLNPs revealed a disappearance of the characteristic sharp melting peak of pure ANS, supporting the incorporation of the drug into the polymeric matrices of the nanoparticles. Flow cytometry showed the apoptosis of MCF-7 cell lines in the presence of ANS-PLNPs. Conclusion: PEGylated polymeric nanoparticles presented a stable encapsulated system with which to incorporate an anticancer drug (ANS) with a high percentage of entrapment efficiency (around 80%), good size uniformity, and induction of apoptosis in MCF-7 cells.

4 May 2021 in Molecules
Verified
Journal Article
Open access
PDF file
OMOsman Mohamed
Osman Mohamed
RARAISUDDIN ALI
RAISUDDIN ALI
AAAbdullah AlOmrani
Abdullah AlOmrani
Aws AlshamsanAws Alshamsan
Aws Alshamsan
Abdullah AlshememryAbdullah Alshememry
Abdullah Alshememry
ZBZiyad Binkhathlan
Ziyad Binkhathlan
The objective of this study was to synthesize and characterize a set of biodegradable block copolymers based on TPGS-block-poly(ε-caprolactone) (TPGS-b-PCL) and to assess their self-assembled structures as a nanodelivery system for paclitaxel (PAX). The conjugation of PCL to TPGS was hypothesized to increase the stability and the drug solubilization characteristics of TPGS micelles. TPGS-b-PCL copolymer with various PCL/TPGS ratios were synthesized via ring opening bulk polymerization of ε-caprolactone using TPGS, with different molecular weights of PEG (1–5 kDa), as initiators and stannous octoate as a catalyst. The synthesized copolymers were characterized using 1H NMR, GPC, FTIR, XRD, and DSC. Assembly of block copolymers was achieved via the cosolvent evaporation method. The self-assembled structures were characterized for their size, polydispersity, and CMC using dynamic light scattering (DLS) technique. The results from the spectroscopic and thermal analyses confirmed the successful synthesis of the copolymers. Only copolymers that consisted of TPGS with PEG molecular weights ≥ 2000 Da were able to self-assemble and form nanocarriers of ≤200 nm in diameter. Moreover, TPGS2000-b-PCL4000, TPGS3500-b-PCL7000, and TPGS5000-b-PCL15000 micelles enhanced the aqueous solubility of PAX from 0.3 µg/mL up to 88.4 ug/mL in TPGS5000-b-PCL15000. Of the abovementioned micellar formulations, TPGS5000-b-PCL15000 showed the slowest in vitro release of PAX. Specifically, the PAX-loaded TPGS5000-b-PCL15000 micellar formulation showed less than 10% drug release within the first 12 h, and around 36% cumulative drug release within 72 h compared to 61% and 100% PAX release, respectively, from the commercially available formulation (Ebetaxel®) at the same time points. Our results point to a great potential for TPGS-b-PCL micelles to efficiently solubilize and control the release of PAX.